ATC Group: L04AB Tumor necrosis factor alpha (TNF-α) inhibitors

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AB in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AB Tumor necrosis factor alpha (TNF-α) inhibitors

Group L04AB contents

Code Title
L04AB01 Etanercept
L04AB02 Infliximab
L04AB03 Afelimomab
L04AB04 Adalimumab
L04AB05 Certolizumab pegol
L04AB06 Golimumab
L04AB07

Active ingredients in L04AB

Active Ingredient Description
Adalimumab

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM).

Afelimomab

Afelimomab is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.

Certolizumab pegol

Certolizumab pegol has a high affinity for human TNFα and binds with a dissociation constant (KD) of 90 pM. TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes. Certolizumab pegol was shown to neutralise membrane associated and soluble human TNFα in a dose-dependent manner. By inhibiting the action of TNFα, certolizumab pegol reduces inflammation and other symptoms in patients with rheumatoid arthritis.

Etanercept

Etanercept is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive.

Golimumab

Golimumab is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human TNF-α, which prevents the binding of TNF-α to its receptors.

Infliximab

Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFβ).

Related product monographs

Title Information Source Document Type  
AVSOLA Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
Cimzia 200 mg solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CIMZIA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ENBREL Powder for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
FLIXABI Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
HUKYNDRA 40mg Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
HUKYNDRA 80mg Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
HUMIRA 20mg Solution for injection in pre-filled syringe European Medicines Agency (EU) MPI, EU: SmPC
HUMIRA 40mg/0.4ml Solution for injection in pre-filled syringe / pen European Medicines Agency (EU) MPI, EU: SmPC
HUMIRA 40mg/0.8ml Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
HUMIRA 40mg/0.8ml Solution for injection in pre-filled syringe / pen European Medicines Agency (EU) MPI, EU: SmPC
HUMIRA 80mg Solution for injection in pre-filled syringe / pen European Medicines Agency (EU) MPI, EU: SmPC
IDACIO Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
INFLECTRA Powder for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
LIBMYRIS 40 mg Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
LIBMYRIS 80 mg Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
RENFLEXIS Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
SIMPONI 50mg Solution for injection in pre-filled syringe / pen European Medicines Agency (EU) MPI, EU: SmPC
YUFLYMA 40 mg Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ZESSLY Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC